Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6012 in stable atherosclerotic cardiovascular disease
NCT03004638Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human lecithin-cholesterol acyltransferase in atherosclerotic cardiovascular disease (ASCVD), sponsored by MedImmune. Started Jan 2017; status: completed.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT03004638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004638.